Market News & Trends
Zogenix Announces Completion of Enrollment for ZX002 Phase III Efficacy Study
Zogenix, Inc. recently announced the completion of enrollment in its pivotal Phase III efficacy study (Study 801) of ZX002. ZX002 is a novel, oral, single-entity,…
2/1/2011
Ligand Pharmaceuticals Forms Drug Development Alliance With Chiva PharmaceuticalsLigand Pharmaceuticals, Inc. recently announced it has entered into a strategic relationship with Chiva Pharmaceuticals, Inc. to…
AndroScience Awarded NIH Grant to Develop Oral Treatment for Kennedy's Disease
AndroScience Corp. recently announced receiving a $3.8-million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the…
Catalent Announces Partnership With Nuron Biotech
Catalent Pharma Solutions, a leading provider of drug and biologic development services, delivery technologies, and supply solutions, recently announced it has entered into an agreement…
Depomed Announces US FDA Approval of Once-Daily Tablets for Post-Herpetic Neuralgia
Depomed, Inc. recently announced the US FDA has approved Gralise (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia (PHN), which is pain following healing of…
Elestrin Estradiol Gel to be Launched in US With LABLABO's Airless Metering Dispenser
Azur Pharma recently launched a new Hormonal Replacement Treatment (HRT) on the US market, Elestrin 0.06% Estradiol Gel. A close collaboration with this Irish lab…
Ligand Pharmaceuticals Forms Drug Development Alliance With Chiva Pharmaceuticals
Ligand Pharmaceuticals, Inc. recently announced it has entered into a strategic relationship with Chiva Pharmaceuticals, Inc. to develop multiple Ligand assets and technology in China…
Merck Serono & Domain Therapeutics to Develop Drugs for Parkinson's Disease
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, recently announced an exclusive development and licensing agreement with Domain Therapeutics, Strasbourg, France, to develop metabotropic…
Amgen & Xencor to Co-Develop Novel Antibody; Deal Worth $500 Million
Xencor, Inc. and Amgen recently announced they will collaborate to develop XmAb5871, an Fc-engineered monoclonal antibody dually targeting CD19 and CD32b. XmAb5871 is currently in…
Evonik & Boehringer Ingelheim Sign Agreement on the Sale of Resomer Business
Evonik Industries and Boehringer Ingelheim Pharma GmbH & Co. KG recently signed an agreement on the sale of the Resomer® business to Evonik. The completion…
NuSil Announces Two New Thermally Conductive Silicones
NuSil Technology LLC, a global leader in silicone materials for the healthcare and pharmaceutical industries, recently introduced two thermally conductive healthcare silicone elastomers. These elastomers…
Synageva BioPharma & to-BBB to Collaborate on Brain Drug Delivery for Rare Diseases
Synageva BioPharma Corp. and to-BBB technologies BV, the Dutch drug brain delivery company, have recently entered into a research collaboration to evaluate the potential of…
TransPharma Announces Successful Results of a Phase I Clinical Trial for Musculoskeletal Disorders
TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, recently…
ZIOPHARM & Intrexon Announce Worldwide Partnership for Synthetic Biology DNA-Based Oncology Therapeutics
ZIOPHARM Oncology, Inc., a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next-generation synthetic biology company, recently announced a global exclusive channel…
1/18/2011
Amgen & Xencor to Co-Develop Novel Antibody; Deal Worth $500 Million Xencor, Inc. and Amgen recently announced they will collaborate to develop XmAb5871, an Fc-engineered monoclonal…
3M DDS Signs Licensing Agreement With Spirig Pharma AG
3M Drug Delivery Systems recently announced it has signed an exclusive licensing agreement with Spirig Pharma AG, a Swiss manufacturer of dermatological and dermocosmetic products.…
Elan Pays Transition Therapeutics $9 Million in Amended Deal for Phase II Candidate
Transition Therapeutics Inc. recently announced the company and Elan Corporation, plc have mutually agreed to modify their collaboration agreement for the development and commercialization of…
Itamar Medical & Roche Sign Agreement For EndoPAT Devices in Preclinical Drug Development
Itamar Medical, a leader in non-invasive vascular health diagnostics, recently announced that an agreement has been signed with Roche by which Itamar will develop an…
Ligand Pharmaceuticals Earns $1 Million Up-Front Payment From Pfizer
Ligand Pharmaceuticals Incorporated recently announced its partner Pfizer, Inc. has granted a sublicense to a multinational pharmaceutical company for Tanaproget, also known as NSP-989. As…
Novo Nordisk & Emisphere Announce License Agreement to Develop Oral Formulation of Insulin for $57.5 Million
Emisphere Technologies, Inc. and Novo Nordisk A/S recently announced they have entered into an exclusive development and license agreement to develop and commercialize oral formulations…
